Janux Therapeutics (JANX) Leases (2021 - 2025)
Historic Leases for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $18.9 million.
- Janux Therapeutics' Leases fell 387.59% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year decrease of 387.59%. This contributed to the annual value of $19.3 million for FY2024, which is 744.79% down from last year.
- Latest data reveals that Janux Therapeutics reported Leases of $18.9 million as of Q3 2025, which was down 387.59% from $18.5 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Leases registered a high of $22.8 million during Q2 2022, and its lowest value of $130000.0 during Q1 2022.
- In the last 5 years, Janux Therapeutics' Leases had a median value of $20.1 million in 2024 and averaged $17.0 million.
- Its Leases has fluctuated over the past 5 years, first soared by 1676692.31% in 2023, then plummeted by 804.4% in 2025.
- Quarter analysis of 5 years shows Janux Therapeutics' Leases stood at $185000.0 in 2021, then surged by 11942.7% to $22.3 million in 2022, then dropped by 6.47% to $20.8 million in 2023, then fell by 7.45% to $19.3 million in 2024, then fell by 1.88% to $18.9 million in 2025.
- Its Leases stands at $18.9 million for Q3 2025, versus $18.5 million for Q2 2025 and $18.9 million for Q1 2025.